{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:26:00Z","timestamp":1750843560637,"version":"3.40.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer de Colombia","award":["0017"],"award-info":[{"award-number":["0017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction\/objectives<\/jats:title><jats:p>The objective of this study is to describe the treatment patterns and use of healthcare resources in a cohort of Colombian patients with rheumatoid arthritis (RA) treated with biological disease-modifying antirheumatic drugs (bDMARDs) or tofacitinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This is a descriptive study from a retrospective cohort of patients diagnosed with RA who were treated with bDMARDs or tofacitinib after failure of conventional DMARDs (cDMARDs) or first bDMARD. Patients who were receiving pharmacological treatment between 01 January 2014 and 30 June 2018 were included. The analysis is through the revision of claim database and electronical medical records. Demographic and clinical data were collected. The costs of healthcare resources were estimated from the billing expense of healthcare service provider.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We evaluated 588 RA patients on treatment with bDMARDs (<jats:italic>n<\/jats:italic>= 505) or tofacitinib (<jats:italic>n<\/jats:italic>= 83), most of them were in combination with cDMARDs (85.4%). The 88.1% were females and mean age was 57.3 \u00b1 12.5 years. The median evolution of RA since diagnosis was 9 years (IQR:4\u201317.2). The mean duration of use during follow-up of the bDMARDs or tofacitinib was similar, with a mean of 9.8 \u00b1 1.9 months. It was identified that 394 (67.0%) discontinued therapy. The average annual direct cost of care per patient was USD 8997 \u00b1 2172, where 97.2% was due to drug costs. The average annual cost of treatment per patient with bDMARDs was USD 8604 and tofacitinib was USD 6377.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In the face of a first failure of cDMARD, bDMARDs are frequently added. A high frequency of patients do not persist treatment during the first year of follow-up. The pharmacological treatment is the most representative cause of healthcare costs.<jats:table-wrap><jats:table><jats:tbody><jats:tr><jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 Rheumatoid arthritis is a disease with a high burden of comorbidities, complications, and worse health-related quality of life and is associated with elevated healthcare costs<\/jats:italic>.<jats:italic>\u2022 The biological disease-modifying antirheumatic drugs or tofacitinib medications are indicated for those with significant progression of the disease and when there is a need for alternatives to achieve low levels of activity and remission<\/jats:italic>.<jats:italic>\u2022 Patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs or tofacitinib represent a significant economic burden to the health system, especially in the costs derived from pharmacological treatment<\/jats:italic>.<\/jats:td><\/jats:tr><\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p><\/jats:sec>","DOI":"10.1007\/s10067-020-05432-6","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T13:04:20Z","timestamp":1601471060000},"page":"1273-1281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-0936","authenticated-orcid":false,"given":"Jorge Enrique","family":"Machado-Alba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8458-0986","authenticated-orcid":false,"given":"Manuel E.","family":"Machado-Duque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2500-7658","authenticated-orcid":false,"given":"Andres","family":"Gaviria-Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia Casta\u00f1o","family":"Gamboa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"5432_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094\u20131108. https:\/\/doi.org\/10.1016\/S0140-6736(10)60826-4","journal-title":"Lancet"},{"key":"5432_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.rcreu.2015.05.006","volume":"22","author":"JE Machado-Alba","year":"2015","unstructured":"Machado-Alba JE, Ruiz AF, Medina Morales DA (2015) The epidemiology of rheumatoid arthritis in a cohort of Colombian patients. Rev Colomb Reumatol 22:148\u2013152. https:\/\/doi.org\/10.1016\/j.rcreu.2015.05.006","journal-title":"Rev Colomb Reumatol"},{"key":"5432_CR3","first-page":"783","volume":"23","author":"L Bazzichi","year":"2005","unstructured":"Bazzichi L, Maser J, Piccinni A, Rucci P, del Debbio A, Vivarelli L, Catena M, Bouanani S, Merlini G, Bombardieri S, Dell'Osso L (2005) Quality of life in rheumatoid arthritis: impact of disability and lifetime depressive spectrum symptomatology. Clin Exp Rheumatol 23:783\u2013788","journal-title":"Clin Exp Rheumatol"},{"key":"5432_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00296-008-0673-x","volume":"29","author":"K Laas","year":"2009","unstructured":"Laas K, Roine R, Rasanen P, Sintonen H, Leirisalo-Repo M (2009) Health-related quality of life in patients with common rheumatic diseases referred to a university clinic. Rheumatol Int 29:267\u2013273. https:\/\/doi.org\/10.1007\/s00296-008-0673-x","journal-title":"Rheumatol Int"},{"key":"5432_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/ijcp.12809","volume":"70","author":"J Machado-Alba","year":"2016","unstructured":"Machado-Alba J, Ruiz A, Machado-Duque M (2016) Effectiveness of treatment with biologic-and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia. Int J Clin Pract 70:506\u2013511. https:\/\/doi.org\/10.1111\/ijcp.12809","journal-title":"Int J Clin Pract"},{"key":"5432_CR6","first-page":"1241","volume":"34","author":"T Uhlig","year":"2007","unstructured":"Uhlig T, Loge JH, Kristiansen IS, Kvien TK (2007) Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol 34:1241\u20131247","journal-title":"J Rheumatol"},{"issue":"5 Suppl 46","key":"5432_CR7","first-page":"S22","volume":"25","author":"M Dougados","year":"2007","unstructured":"Dougados M, Aletaha D, van Riel P (2007) Disease activity measures for rheumatoid arthritis. Clin Exp Rheumatol 25(5 Suppl 46):S22\u2013S29","journal-title":"Clin Exp Rheumatol"},{"key":"5432_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0092-8674(00)81109-5","volume":"85","author":"M Feldmann","year":"1996","unstructured":"Feldmann M, Brennan FM, Maini RN (1996) Rheumatoid arthritis. Cell 85:307\u2013310. https:\/\/doi.org\/10.1016\/S0092-8674(00)81109-5","journal-title":"Cell"},{"key":"5432_CR9","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/art.21118","volume":"52","author":"TC Tolboom","year":"2005","unstructured":"Tolboom TC, van der Helm-Van Mil AH, Nelissen RG, Breedveld FC, Toes RE, Huizinga TW (2005) Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis. Arthritis Rheum 52:1999\u20132002. https:\/\/doi.org\/10.1002\/art.21118","journal-title":"Arthritis Rheum"},{"key":"5432_CR10","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/acr.22638","volume":"67","author":"M Bonafede","year":"2015","unstructured":"Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH (2015) Etanercept-methotrexate combination therapy initiators have greater adherence and persistence than triple therapy initiators with rheumatoid arthritis. Arthritis Care Res (Hoboken) 67:1656\u20131663. https:\/\/doi.org\/10.1002\/acr.22638","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5432_CR11","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M, Zwillich S (2016) The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34:318\u2013328","journal-title":"Clin Exp Rheumatol"},{"key":"5432_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12891-015-0636-9","volume":"16","author":"HG N\u00fc\u00dflein","year":"2015","unstructured":"N\u00fc\u00dflein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, le Bars M (2015) Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskelet Disord 16:176. https:\/\/doi.org\/10.1186\/s12891-015-0636-9","journal-title":"BMC Musculoskelet Disord"},{"key":"5432_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.reuma.2016.04.010","volume":"13","author":"SC Radominski","year":"2017","unstructured":"Radominski SC, Cardiel MH, Citera G, Goecke A, Jaller JJ, Lomonte ABV, Miranda P, Velez P, Xibill\u00e9 D, Kwok K, Rojo R, Garc\u00eda EG (2017) Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: pooled efficacy and safety analyses of phase 3 and long-term extension studies. Reumatol Clin 13:201\u2013209. https:\/\/doi.org\/10.1016\/j.reuma.2016.04.010","journal-title":"Reumatol Clin"},{"key":"5432_CR14","first-page":"396","volume":"36","author":"JE Machado-Alba","year":"2014","unstructured":"Machado-Alba JE, Ruiz AF, Machado-Duque ME (2014) Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Rev Panam Salud Publica 36:396\u2013401","journal-title":"Rev Panam Salud Publica"},{"key":"5432_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.18553\/jmcp.2016.22.9.1088","volume":"22","author":"L Claxton","year":"2016","unstructured":"Claxton L, Jenks M, Taylor M et al (2016) An economic evaluation of tofacitinib treatment in rheumatoid arthritis: modeling the cost of treatment strategies in the United States. J Manag Care Spec Pharm 22:1088\u20131102. https:\/\/doi.org\/10.18553\/jmcp.2016.22.9.1088","journal-title":"J Manag Care Spec Pharm"},{"key":"5432_CR16","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.23512","volume":"70","author":"A Hresko","year":"2018","unstructured":"Hresko A, Lin TC, Solomon DH (2018) Medical care costs associated with rheumatoid arthritis in the US: a systematic literature review and meta-analysis. Arthritis Care Res (Hoboken) 70:1431\u20131438. https:\/\/doi.org\/10.1002\/acr.23512","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5432_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0121-8123(11)70060-3","volume":"18","author":"N Montoya","year":"2011","unstructured":"Montoya N, G\u00f3mez L, V\u00e9lez M, Rosselli D (2011) Costos directos del tratamiento de pacientes con artritis reumatoide en Medell\u00edn, Colombia. Rev Colomb Reumatol 18:26\u201333. https:\/\/doi.org\/10.1016\/S0121-8123(11)70060-3","journal-title":"Rev Colomb Reumatol"},{"key":"5432_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/pds.1230","volume":"15","author":"SE Andrade","year":"2006","unstructured":"Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15:565\u2013577. https:\/\/doi.org\/10.1002\/pds.1230","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5432_CR19","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1136\/ard.62.10.944","volume":"62","author":"D Aletaha","year":"2003","unstructured":"Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, Smolen JS (2003) Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 62:944\u2013951. https:\/\/doi.org\/10.1136\/ard.62.10.944","journal-title":"Ann Rheum Dis"},{"key":"5432_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.clinthera.2011.06.001","volume":"33","author":"MA Blum","year":"2011","unstructured":"Blum MA, Koo D, Doshi JA (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33:901\u2013913. https:\/\/doi.org\/10.1016\/j.clinthera.2011.06.001","journal-title":"Clin Ther"},{"key":"5432_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/pds.3935","volume":"25","author":"MJ Bijlsma","year":"2016","unstructured":"Bijlsma MJ, Janssen F, Hak E (2016) Estimating time-varying drug adherence using electronic records: extending the proportion of days covered (PDC) method. Pharmacoepidemiol Drug Saf 25:325\u2013332. https:\/\/doi.org\/10.1002\/pds.3935","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5432_CR22","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St.Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 68:1\u201326","journal-title":"Arthritis Rheumatol"},{"key":"5432_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/rheumatology\/key298","volume":"58","author":"CR Holroyd","year":"2019","unstructured":"Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, Chan C, Yusuf MA, Litwic A, Smolen S, Topliffe J, Bennett S, Humphreys J, Green M, Ledingham J (2019) The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology (Oxford) 58:372. https:\/\/doi.org\/10.1093\/rheumatology\/key298","journal-title":"Rheumatology (Oxford)"},{"key":"5432_CR24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s11255-011-0085-9","volume":"44","author":"M Rattanasompattikul","year":"2012","unstructured":"Rattanasompattikul M, Feroze U, Molnar MZ, Dukkipati R, Kovesdy CP, Nissenson AR, Norris KC, Kopple JD, Kalantar-Zadeh K (2012) Charlson comorbidity score is a strong predictor of mortality in hemodialysis patients. Int Urol Nephrol 44:1813\u20131823. https:\/\/doi.org\/10.1007\/s11255-011-0085-9","journal-title":"Int Urol Nephrol"},{"key":"5432_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s41927-018-0014-y","volume":"2","author":"A Jagpal","year":"2018","unstructured":"Jagpal A, Navarro-Millan I (2018) Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol 2:10. https:\/\/doi.org\/10.1186\/s41927-018-0014-y","journal-title":"BMC Rheumatol"},{"key":"5432_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2017-212392","volume":"77","author":"JM Weijers","year":"2018","unstructured":"Weijers JM, Rongen-van Dartel SAA, Hoevenaars D, Rubens M, Hulscher M, van Riel P (2018) Implementation of the EULAR cardiovascular risk management guideline in patients with rheumatoid arthritis: results of a successful collaboration between primary and secondary care. Ann Rheum Dis 77:480\u2013483. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212392","journal-title":"Ann Rheum Dis"},{"key":"5432_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2174\/1570161117666190619143842","volume":"18","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, Panayotidis I, Nikiphorou E (2019) Cardiovascular risk in rheumatoid arthritis and mechanistic links: from pathophysiology to treatment. Curr Vasc Pharmacol 18:431\u2013446. https:\/\/doi.org\/10.2174\/1570161117666190619143842","journal-title":"Curr Vasc Pharmacol"},{"key":"5432_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/03009742.2019.1600718","volume":"48","author":"M Heslinga","year":"2019","unstructured":"Heslinga M, Van Den Oever I, Jonker DL et al (2019) Suboptimal cardiovascular risk management in rheumatoid arthritis patients despite an explicit cardiovascular risk screening programme. Scand J Rheumatol 48:345\u2013352. https:\/\/doi.org\/10.1080\/03009742.2019.1600718","journal-title":"Scand J Rheumatol"},{"key":"5432_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tcm.2016.07.006","volume":"27","author":"KP Liao","year":"2017","unstructured":"Liao KP (2017) Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med 27:136\u2013140. https:\/\/doi.org\/10.1016\/j.tcm.2016.07.006","journal-title":"Trends Cardiovasc Med"},{"key":"5432_CR30","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.clinthera.2016.01.022","volume":"38","author":"G Kim","year":"2016","unstructured":"Kim G, Barner JC, Rascati K, Richards K (2016) Examining time to initiation of biologic disease-modifying antirheumatic drugs and medication adherence and persistence among Texas Medicaid recipients with rheumatoid arthritis. Clin Ther 38:646\u2013654. https:\/\/doi.org\/10.1016\/j.clinthera.2016.01.022","journal-title":"Clin Ther"},{"key":"5432_CR31","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1097\/RHU.0000000000001093","volume":"10","author":"P Santos-Moreno","year":"2019","unstructured":"Santos-Moreno P, Sanchez-Vanegas G (2019) Clinical effectiveness and safety of treatment with anti-tumor necrosis factor alpha drugs in a cohort of Colombian patients with rheumatoid arthritis. J Clin Rheumatol 10:1097. https:\/\/doi.org\/10.1097\/RHU.0000000000001093","journal-title":"J Clin Rheumatol"},{"key":"5432_CR32","doi-asserted-by":"crossref","unstructured":"del Moral RC, Rillo OL, Benegas M et al (2013) Adherencia al tratamiento de pacientes con artritis reumatoidea que reciben medicamentos biol\u00f3gicos. Rev Argent Reumatol 24(4)","DOI":"10.47196\/rar.v24i4.42"},{"key":"5432_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.18553\/jmcp.2019.25.4.461","volume":"25","author":"I Khilfeh","year":"2019","unstructured":"Khilfeh I, Guyette E, Watkins J, Danielson D, Gross D, Yeung K (2019) Adherence, persistence, and expenditures for high-cost anti-Inflammatory drugs in rheumatoid arthritis: an exploratory study. J Manag Care Spec Pharm 25:461\u2013467. https:\/\/doi.org\/10.18553\/jmcp.2019.25.4.461","journal-title":"J Manag Care Spec Pharm"},{"key":"5432_CR34","unstructured":"Ministerio de Salud y Protecci\u00f3n Social de Colombia (2016). Resoluci\u00f3n N\u00famero 006411 de 2016, Valor de la Unidad de Pago por Capitaci\u00f3n (UPC) vigencia de 2017. Available: https:\/\/diario-oficial.vlex.com.co\/vid\/resolucion-numero-006411-2016-656478197 (Accessed 17 Jan 2020)"},{"issue":"1","key":"5432_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.reumae.2016.09.004","volume":"14","author":"L Leon","year":"2018","unstructured":"Leon L, Abasolo L, Fernandez-Gutierrez B, Jover JA, Hernandez-Garcia C (2018) Direct medical costs and their predictors in the EMAR-II cohort: \u201cvariability in the management of rheumatoid arthritis and spondyloarthritis in Spain\u201d. Reumatol Clin 14(1):4\u20138. https:\/\/doi.org\/10.1016\/j.reumae.2016.09.004","journal-title":"Reumatol Clin"},{"key":"5432_CR36","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s12325-016-0312-y","volume":"33","author":"B Chastek","year":"2016","unstructured":"Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS (2016) A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients. Adv Ther 33:626\u2013642. https:\/\/doi.org\/10.1007\/s12325-016-0312-y","journal-title":"Adv Ther"},{"key":"5432_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.21115\/JBES.v11.n2.p105-11","volume":"11","author":"P Yazawa","year":"2019","unstructured":"Yazawa P, Puopolo G, Walmrath J, Leme-Souza R, Bianco J (2019) Cost-minimization analysis of biological disease-modifying antirheumatic drugs in the Brazilian public health system (SUS) considering patients\u2019 weight. J Bras Econ Sa\u00fade 11:105\u2013111. https:\/\/doi.org\/10.21115\/JBES.v11.n2.p105-11","journal-title":"J Bras Econ Sa\u00fade"},{"key":"5432_CR38","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s10067-017-3725-3","volume":"36","author":"A Syngle","year":"2017","unstructured":"Syngle A, Kaur S, Verma I, Syngle T, Syngle V (2017) Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Clin Rheumatol 36:1715\u20131720. https:\/\/doi.org\/10.1007\/s10067-017-3725-3","journal-title":"Clin Rheumatol"},{"key":"5432_CR39","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5114\/reum.2018.80710","volume":"56","author":"K Kowalik","year":"2018","unstructured":"Kowalik K, Wegierska M, Barczynska T, Jeka S (2018) Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment. Reumatologia 56:340\u2013345. https:\/\/doi.org\/10.5114\/reum.2018.80710","journal-title":"Reumatologia"},{"key":"5432_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10067-016-3470-z","volume":"36","author":"M Husberg","year":"2017","unstructured":"Husberg M, Davidson T, Hallert E (2017) Non-medical costs during the first year after diagnosis in two cohorts of patients with early rheumatoid arthritis, enrolled 10 years apart. Clin Rheumatol 36:499\u2013506. https:\/\/doi.org\/10.1007\/s10067-016-3470-z","journal-title":"Clin Rheumatol"},{"key":"5432_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/OARRR.S164738","volume":"10","author":"W Fakhouri","year":"2018","unstructured":"Fakhouri W, Lopez-Romero P, Antonelli S, Losi S, Rogai V, Buda S, Sangiorgi D, Perrone V, Degli Esposti L (2018) Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis. Open Access Rheumatol 10:103\u2013111. https:\/\/doi.org\/10.2147\/OARRR.S164738","journal-title":"Open Access Rheumatol"},{"key":"5432_CR42","first-page":"1033","volume":"34","author":"V Hamuryudan","year":"2016","unstructured":"Hamuryudan V, Direskeneli H, Ertenli I, Inanc M, Karaaslan Y, Oksel F, Ozbek S, Pay S, Terzioglu E, Balkan Tezer D, Hacibedel B, Akkoc N (2016) Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey. Clin Exp Rheumatol 34:1033\u20131037","journal-title":"Clin Exp Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05432-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05432-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05432-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T10:33:09Z","timestamp":1669026789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05432-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["5432"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05432-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"10 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work was funded by Pfizer. Pfizer did not participate in the management or data analysis of the study information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}